
THE FLIXONASE®
DIFFERENCE
DOSAGE:
Age 18 or older

Use two sprays into each nostril once a day. Do not use more than two sprays into each nostril per day. Do not use more than the recommended dose. |

It is important that you use the nasal spray regularly for the recommended treatment duration. |
WARNINGS
Only for use in the nose. Do not spray into your eyes or mouth. |
DO NOT USE
Do not use Flixonase if you have a known sensitivity to any of its ingredients, or a history of allergic reaction to other corticosteroids. |
TAKE SPECIAL CARE AND CHECK WITH YOUR DOCTOR BEFORE YOU TAKE THIS MEDICINE: |
---|
If you have a high temperature, cold or have been diagnosed with a sinus infection. |
If you have ever had an allergic reaction to FLIXONASE® Allergy & Hayfever Relief or any of its ingredients. |
If you have recently had surgery or an injury to the nose, or ulcers in the nose. |
If you have or have recently suffered from a nasal infection in or around the nose. |
If you are pregnant or planning to become pregnant. |
If you are breastfeeding. |
If you are taking ritonavir (a medicine used to treat HIV) unless told to do so by your doctor. |
If you are using ketoconazole (used to treat fungal infections) unless told to do so by your doctor. |
If you are using other corticosteroid medicines – these may include some eczema creams, asthma inhalers, tablets, injections, nasal sprays, and eye or nose drops. |
You should tell your doctor about all of the medications you take including FLIXONASE® Allergy & Hayfever Relief. |
There are a few medicines to look out for because they may cause the level of FLIXONASE® Allergy & Hayfever Relief in your body to become too high. |
Check this table:
IF YOU'RE TAKING: | HERE'S WHAT TO DO: |
---|---|
Medicines for HIV infection (such as ritonavir) | Talk to your doctor or pharmacist before using FLIXONASE® Allergy & Hayfever Relief. |
Tablets for fungal infection |
Talk to your doctor or pharmacist before using FLIXONASE® Allergy & Hayfever Relief. |
Other corticosteroid medicines – these may include some eczema creams, asthma inhalers, tablets, injections, nasal sprays, and eye or nose drops | Talk to your doctor or pharmacist before using FLIXONASE® Allergy & Hayfever Relief. |
Refer to the Consumer Medicine Information for further information.
Serious side effects are rare with FLIXONASE® Allergy & Hayfever Relief because FLIXONASE® Allergy & Hayfever Relief works in your nose and barely any of it travels through your body. However, like all medicines, FLIXONASE® can cause side effects in some people. Below are some side effects that have been reported with FLIXONASE®. If you have any concerns about side effects, talk with your doctor. |
When using this product you may experience: |
---|
|
Stop taking this medicine and tell your doctor immediately if: |
---|
|
IF YOU USE MORE MEDICINE THAN RECOMMENDED: |
---|
|
Flixonase contains fluticasone propionate 50 mcg per spray for the prevention and treatment of seasonal and allergic rhinitis including hayfever.ALWAYS READ THE LABEL. Use only as directed. If symptoms persist see your healthcare professional.
Flixonase is a registered trademark of the GSK group of companies or its licensor. Auckland, New Zealand. TAPS BG1062
Trade marks are owned by or licensed to the GSK group of companies. ©2021 GSK group of companies or its licensor.
Flixonase contains fluticasone propionate 50mcg per spray. ALWAYS READ THE LABEL. Use only as directed. For the prevention and treatment of seasonal and allergic rhinitis including hayfever. If symptoms persist, see your healthcare professional.
Flixonase is a registered trademark of the GSK group of companies or its licensor. Auckland, New Zealand. TAPS XXXXXXX
The information on this site is intended for visitors from New Zealand only. See our Terms and Conditions and Privacy Policy.
1. Australian Medicines Handbook 2016, AMH Pty Ltd; Adelaide. 2. Bousquet J et al. Allergy 2008;63(Suppl 86):8–160. 3. Wallace DV et al. J Allergy Clin Immunol 2008;122:S1–84. 4. Bachert C & Geveart P. Allergy 1999;54(Suppl 57):116–23. 5. Wiseman LR & Benfield P. Drugs1997;53:885–907.